Nuance Pharma
PrivateLast Round
Series E
Jul 22, 2025
Est. Valuation
$620.7M
Total Funding Raised
$216M
Company Overview
Nuance Pharma operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Strategic round in June 2021.
Nuance Pharma is a specialty pharmaceutical company that develops and commercializes innovative therapies for respiratory, emergency care, iron deficiency anemia, and pain management.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuance Pharma Comparables
Compare Nuance Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SciClone Pharmaceuticals (Holdings) Limited | 70% | |
| Zai Lab Limited | 69% | |
| Stallergenes Greer | 67% |
For institutional investors. Book with your work email.
Nuance Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Jul 22, 2025 | ||||
| Strategic | Jun 10, 2021 | ||||
| Series D | Dec 8, 2020 | ||||
| Series B | Jun 27, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nuance Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CBC Group | Series D, Series B |
| HBM Healthcare Investments | Series D, Series B |
| MPC | Series D |
| RTW Investments | Series D |
| nebag ag | Series B |
| HBM Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 1, 2024
Ohtuvayre launched via early access in Hainan Boao Pilot Zone.
- Jun 10, 2021
$15M raised with Verona Pharma plc
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 18, 2026
Nuance Pharma and Stallergenes Greer partner on pivotal Actair(R) studies in China, with the studies beginning in Oct '26.
For institutional investors. Book with your work email.
Nuance Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nuance Pharma's valuation, stock price, and market status.
Is Nuance Pharma a public or private company?
Nuance Pharma is a private company.
What is the current stock price of Nuance Pharma?
Nuance Pharma is a private company, so its shares have no public market price. Caplight tracks Nuance Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nuance Pharma worth (valuation)?
Nuance Pharma's valuation is estimated at $620.7M based on funding round data.
Can I buy Nuance Pharma stock?
Nuance Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nuance Pharma's last funding round?
Nuance Pharma's most recent funding round was Series E on July 22, 2025.
Who are the main investors in Nuance Pharma?
Key investors in Nuance Pharma include CBC Group, RTW Investments.
Will Nuance Pharma IPO soon?
No public IPO plans have been announced for Nuance Pharma.
How can I track Nuance Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Nuance Pharma's shares on secondary markets.